Finance

Lists
A1RG34:BVMF
Argenx Se Bdr
187,38 R$
+1,99%
(+3,65) 1D
6 қаз., 14:05:54 GMT-3  ·   BRL
All symbols
SymbolPriceChange% Change
Generating top insights for A1RG34...
Open
187,38 R$
High
187,38 R$
Low
187,38 R$
Mkt. cap
58,68 млрд
Avg. vol.
57,00
Volume
10,00
52-wk high
213,15 R$
52-wk low
143,22 R$
Shares outstanding
62,56 млн
No. of employees
2 мың
Open
187,38 R$
High
187,38 R$
Low
187,38 R$
Mkt. cap
58,68 млрд
Avg. vol.
57,00
Volume
10,00
52-wk high
213,15 R$
52-wk low
143,22 R$
Shares outstanding
62,56 млн
No. of employees
2 мың
News stories
From web sources and news partners
Profile
Argenx SE is a Belgian-Dutch pharmaceutical company specializing in immunology. Argenx specializes in the development of antibody therapies for the treatment of autoimmune diseases and cancer. Its work primarily focuses on the development of orphan drugs. Wikipedia
About Argenx Se Bdr
CEO-
Employees1,86 мың
Founded2008 ж. 25 сәу.
Headquarters-
Sector-
Websiteargenx.com
Last report
2026 ж. 23 шіл.
Fiscal period
Q2 2026
EPS / Est. (USD)
7,32 $ / 6,52 $
+12,32%beat
Revenue / Est. (USD)
1,54 млрд / 1,44 млрд
+6,82%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025 ж. қыр.
2025 ж. жел.
2026 ж. нау.
2026 ж. мау.
Revenue
1,15 млрд
1,31 млрд
1,31 млрд
1,54 млрд
Cost of goods sold
465,08 млн
521,40 млн
564,00 млн
631,00 млн
Cost of revenue
465,08 млн
521,40 млн
564,00 млн
631,00 млн
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
336,29 млн
429,62 млн
355,00 млн
417,00 млн
Operating expense
336,29 млн
429,62 млн
355,00 млн
417,00 млн
Total operating expenses
801,37 млн
951,02 млн
919,00 млн
1,05 млрд
Operating income
349,97 млн
359,56 млн
394,00 млн
493,00 млн
Other non operating income
-
-907,00 м.
-
-1,00 млн
EBT including unusual items
386,05 млн
403,29 млн
426,00 млн
531,00 млн
EBT excluding unusual items
386,05 млн
391,71 млн
426,00 млн
531,00 млн
Income tax expense
41,80 млн
-129,66 млн
60,00 млн
59,00 млн
Effective tax rate
10,83%
-32,15%
14,08%
11,11%
Other operating expenses
-
-
-
-
Net income
344,26 млн
532,95 млн
366,00 млн
472,00 млн
Net profit margin
29,90%
40,67%
27,88%
30,63%
Earnings per share
5,18
8,02
5,52
7,32
Interest and investment income
42,70 млн
44,95 млн
44,00 млн
48,00 млн
Interest expense
-993,00 м.
-
-1,00 млн
-1,00 млн
Net interest expenses
41,71 млн
44,95 млн
43,00 млн
47,00 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
350,35 млн
361,38 млн
395,82 млн
501,50 млн
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google қолданбалары